David Lubner
Direktor/Vorstandsmitglied bei ARCELLX, INC.
Vermögen: 3 Mio $ am 31.05.2024
Profil
Mr. David C.
Lubner, CPA, is an Independent Director at Cargo Therapeutics, Inc., an Independent Director at Arcellx, Inc., an Independent Director at Vor Biopharma, Inc., an Independent Director at Gemini Therapeutics Sub, Inc., an Independent Director at Dyne Therapeutics, Inc. and a Member at The American Institute of Certified Public Accountants.
He is on the Board of Directors at Cargo Therapeutics, Inc., Cerevance, Inc., Arcellx, Inc., Vor Biopharma, Inc., Gemini Therapeutics Sub, Inc., Dyne Therapeutics, Inc. and Ichnos Sciences, Inc. Mr. Lubner was previously employed as an Independent Director by POINT Biopharma Global, Inc., an Independent Director by Therapeutics Acquisition Corp., an Independent Director by Gemini Therapeutics, Inc., an Independent Non-Executive Director by Nightstar Therapeutics Plc, a Chief Financial Officer, Secretary & Executive VP by Ra Pharmaceuticals, Inc., a Chief Financial Officer & Senior Vice President by Tetraphase Pharmaceuticals, Inc., a Chief Financial Officer by PharMetrics, Inc., and a Chief Financial Officer & Vice President by ProScript, Inc. He also served on the board at NightstaRx Ltd.
He received his undergraduate degree from Northeastern University and a graduate degree from Bentley University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DYNE THERAPEUTICS INC
0,05% | 22.05.2024 | 53 625 ( 0,05% ) | 2 Mio $ | 31.05.2024 |
ARCELLX, INC.
0,04% | 28.05.2024 | 21 659 ( 0,04% ) | 1 Mio $ | 31.05.2024 |
CARGO THERAPEUTICS, INC.
-.--% | 04.06.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
VOR BIOPHARMA, INC.
-.--% | 23.05.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von David Lubner
| Unternehmen | Position | Beginn |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.03.2020 |
| VOR BIOPHARMA INC. | Direktor/Vorstandsmitglied | 30.07.2020 |
| ARCELLX, INC. | Direktor/Vorstandsmitglied | 01.08.2020 |
| CARGO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.07.2023 |
Gemini Therapeutics Sub, Inc.
 Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 28.04.2020 |
Cerevance, Inc.
 Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | 08.12.2020 |
Ichnos Sciences, Inc.
 Ichnos Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ. | Direktor/Vorstandsmitglied | - |
The American Institute of Certified Public Accountants
 The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von David Lubner
| Unternehmen | Position | Ende |
|---|---|---|
| POIT BIOP | Direktor/Vorstandsmitglied | 27.12.2023 |
| ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von David Lubner
| Northeastern University | Undergraduate Degree |
| Bentley University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| DYNE THERAPEUTICS, INC. | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| POIT BIOP | Health Technology |
| ARCELLX, INC. | Health Technology |
| CARGO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 12 |
|---|---|
PharMetrics, Inc.
 PharMetrics, Inc. Miscellaneous Commercial ServicesCommercial Services PharMetrics, Inc. provided healthcare market insights based on longitudinal and patient-centric information. The company was founded in 1998 and was headquartered in Watertown, MA. | Commercial Services |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
ProScript, Inc.
 ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | Health Technology |
The American Institute of Certified Public Accountants
The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY. | Commercial Services |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Ichnos Sciences, Inc.
Ichnos Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ. | Commercial Services |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Therapeutics Acquisition Corp. is a blank check company with a purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Peter Kolchinsky and Matthew Hammond on April 15, 2020 and is headquartered in Boston, MA. | Finance |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
